Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Breaking Down Case Study Learnings to Optimize Outsourced Bioconjugation & Minimize ADC Production Cost & Timelines

Breaking Down Case Study Learnings to Optimize Outsourced Bioconjugation & Minimize ADC Production Cost & Timelines

2:00 pm - Tuesday 13th October 2026

Understanding the financial and timeline risks associated with outsourced ADC manufacturing
Contextualizing the significance of manufacturing partner selection with two early-stage conjugation program case studies
Laying out adaptations to pivot and resolve conjugation issues to ultimately successfully deliver ADC clinical material

Speakers:

Olga Paley

Olga Paley

Director & Head, US Downstream Process Development & Bioconjugation

Takeda Pharmaceutical